Protocol for a multi-centre, definitive randomised controlled trial of the effectiveness of Individual Placement and Support for employment support among people with alcohol and drug dependence.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
11 Feb 2020
Historique:
received: 03 09 2019
accepted: 21 01 2020
entrez: 13 2 2020
pubmed: 13 2 2020
medline: 24 11 2020
Statut: epublish

Résumé

Unemployment is highly prevalent in populations with alcohol and drug dependence and the employment support offered in addiction-treatment programmes is ineffective. Individual Placement and Support (IPS) is an evidence-based intervention for competitive employment. IPS has been extensively studied in severe mental illness and physical disabilities, but there have been no formal randomised controlled trials (RCTs) in alcohol and drug dependence. The Individual Placement and Support for Alcohol and Drug Dependence (IPS-AD) study should determine whether IPS for patients with alcohol use disorder (AUD), opioid use disorder (OUD) and other drug use disorder is effective. The IPS-AD study is a seven-site, pragmatic, two-arm, parallel-group, superiority RCT. IPS-AD includes a realist process evaluation. Eligible patients (adult, unemployed or economically inactive for at least 6 months and wishing to obtain open job market employment and enrolled in ongoing community treatment-as-usual (TAU; the control condition) in England for AUD, OUD and other drug use disorders) will be randomised (1:1) to receive TAU and any standard employment support, or TAU plus IPS (the experimental condition) for 9 months with up to 4 months of in-work support. The primary outcome measure will be competitive employment status (at least 1 day (7 h)) during an 18-month follow-up, determined by patient-level, trial-data-linkage with national tax and state benefit databases. From meta-analysis, an 18% target difference on this measure of vocational effectiveness (for the experimental intervention) and a two-sided 5% level of statistical significance, will require a minimum target sample of 832 participants to achieve 90% power for a pre-registered, mixed-effects, multi-variable logistic regression model. A maximum-likelihood multiple-imputation approach will manage missing outcome data. IPS-AD has six vocational secondary outcome measures during the 18-month follow-up: (1) total time in competitive employment (and corresponding National Insurance contributions and tax paid); (2) time from randomisation to first competitive employment; (3) number of competitive job appointments; (4) job tenure (length of longest held competitive employment); (5) sustained employment (tenure in a single appointment for at least 13 weeks); and (6) job search self-efficacy. A primary cost-benefit analysis and a secondary cost-effectiveness analysis will be done using the primary outcome and secondary vocational outcomes, respectively and will include addiction treatment and social and health outcomes and their associated reference costs. The process evaluation will address IPS implementation and delivery. The IPS-AD study is the first large-scale, multi-site, definitive, superiority RCT of IPS for people with alcohol and drug dependence. Findings from the study will have substantial implications for service delivery. ISRCTN Registry, ID: ISRCTN24159790. Registered on 1 February 2018.

Sections du résumé

BACKGROUND BACKGROUND
Unemployment is highly prevalent in populations with alcohol and drug dependence and the employment support offered in addiction-treatment programmes is ineffective. Individual Placement and Support (IPS) is an evidence-based intervention for competitive employment. IPS has been extensively studied in severe mental illness and physical disabilities, but there have been no formal randomised controlled trials (RCTs) in alcohol and drug dependence. The Individual Placement and Support for Alcohol and Drug Dependence (IPS-AD) study should determine whether IPS for patients with alcohol use disorder (AUD), opioid use disorder (OUD) and other drug use disorder is effective.
DESIGN/METHODS METHODS
The IPS-AD study is a seven-site, pragmatic, two-arm, parallel-group, superiority RCT. IPS-AD includes a realist process evaluation. Eligible patients (adult, unemployed or economically inactive for at least 6 months and wishing to obtain open job market employment and enrolled in ongoing community treatment-as-usual (TAU; the control condition) in England for AUD, OUD and other drug use disorders) will be randomised (1:1) to receive TAU and any standard employment support, or TAU plus IPS (the experimental condition) for 9 months with up to 4 months of in-work support. The primary outcome measure will be competitive employment status (at least 1 day (7 h)) during an 18-month follow-up, determined by patient-level, trial-data-linkage with national tax and state benefit databases. From meta-analysis, an 18% target difference on this measure of vocational effectiveness (for the experimental intervention) and a two-sided 5% level of statistical significance, will require a minimum target sample of 832 participants to achieve 90% power for a pre-registered, mixed-effects, multi-variable logistic regression model. A maximum-likelihood multiple-imputation approach will manage missing outcome data. IPS-AD has six vocational secondary outcome measures during the 18-month follow-up: (1) total time in competitive employment (and corresponding National Insurance contributions and tax paid); (2) time from randomisation to first competitive employment; (3) number of competitive job appointments; (4) job tenure (length of longest held competitive employment); (5) sustained employment (tenure in a single appointment for at least 13 weeks); and (6) job search self-efficacy. A primary cost-benefit analysis and a secondary cost-effectiveness analysis will be done using the primary outcome and secondary vocational outcomes, respectively and will include addiction treatment and social and health outcomes and their associated reference costs. The process evaluation will address IPS implementation and delivery.
DISCUSSION CONCLUSIONS
The IPS-AD study is the first large-scale, multi-site, definitive, superiority RCT of IPS for people with alcohol and drug dependence. Findings from the study will have substantial implications for service delivery.
TRIAL REGISTRATION BACKGROUND
ISRCTN Registry, ID: ISRCTN24159790. Registered on 1 February 2018.

Identifiants

pubmed: 32046765
doi: 10.1186/s13063-020-4099-4
pii: 10.1186/s13063-020-4099-4
pmc: PMC7014654
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

167

Subventions

Organisme : UK Government (Work and Health Unit)
ID : PHE IPS study

Références

Lancet Psychiatry. 2015 Mar;2(3):239-45
pubmed: 26359902
Psychiatr Rehabil J. 2004 Spring;27(4):345-59
pubmed: 15222147
Psychiatr Serv. 2001 Mar;52(3):313-22
pubmed: 11239097
Am J Public Health. 1998 Nov;88(11):1616-22
pubmed: 9807526
Lancet. 2013 Jan 12;381(9861):91-2
pubmed: 23305999
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Psychother Psychosom. 1980;34(2-3):88-109
pubmed: 7220773
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Br Med J (Clin Res Ed). 1986 Oct 11;293(6552):929-32
pubmed: 3094720
Ind Relat (Berkeley). 2013 Apr;52(2):444-466
pubmed: 23543880
J Health Soc Behav. 1993 Sep;34(3):215-25
pubmed: 7989666
BMC Med. 2010 Mar 24;8:18
pubmed: 20334633
Hosp Community Psychiatry. 1983 May;34(5):438-41
pubmed: 6852792
PLoS One. 2015 Oct 07;10(10):e0140017
pubmed: 26445239
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
J Health Econ. 2000 Nov;19(6):1089-115
pubmed: 11186846
Adm Policy Ment Health. 2017 May;44(3):359-364
pubmed: 28213673
Addiction. 2008 Sep;103(9):1450-60
pubmed: 18783500
Trials. 2018 Nov 5;19(1):606
pubmed: 30400926
Psychiatr Serv. 2012 Aug;63(8):758-63
pubmed: 22660842
PLoS One. 2019 Feb 20;14(2):e0212208
pubmed: 30785954

Auteurs

John Marsden (J)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK. john.marsden@phe.gov.uk.
Addictions Department, Division of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. john.marsden@phe.gov.uk.

Paul Anders (P)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

Helen Clark (H)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

Kyriacos Colocassis (K)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

Brian Eastwood (B)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

Jonathan Knight (J)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

Alexandra Melaugh (A)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

David Quinn (D)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

Virginia Wright (V)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

Jez Stannard (J)

Alcohol, Drugs, Tobacco and Justice Division, Health Improvement, Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH